Skip to main content

PetMed Express Faces Nasdaq Compliance Notice

Tipranks - Fri Nov 14, 2025

Meet Your ETF AI Analyst

Petmed Express ( (PETS) ) has shared an update.

PetMed Express, Inc. announced on November 13, 2025, that it received a notice from Nasdaq due to delays in filing its quarterly reports for periods ending June 30 and September 30, 2025. This non-compliance with Nasdaq’s listing rules requires the company to update its compliance plan by November 28, 2025. The notice does not immediately affect the company’s stock listing, and PetMed is working to complete the filings promptly. Additionally, preliminary second-quarter results indicate a decline in net sales compared to the previous year, with estimated sales ranging from $43.4 million to $44.5 million.

The most recent analyst rating on (PETS) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Petmed Express stock, see the PETS Stock Forecast page.

Spark’s Take on PETS Stock

According to Spark, TipRanks’ AI Analyst, PETS is a Neutral.

Petmed Express faces significant financial challenges with declining revenues and profitability issues, which are the most impactful factors on its stock score. Technical analysis shows some positive momentum, but the stock remains below key moving averages. Valuation is unattractive due to negative earnings and lack of dividends.

To see Spark’s full report on PETS stock, click here.

More about Petmed Express

PetMed Express, Inc., founded in 1996, is a leader in the direct-to-consumer pet healthcare industry. Operating under the PetMeds brand and its subsidiary PetCareRx, the company offers a wide range of pet health solutions, including pharmaceuticals, compounded medications, and nutritional supplements. PetMeds is licensed in all 50 states and focuses on providing value, convenience, and care to pet owners.

Average Trading Volume: 107,182

Technical Sentiment Signal: Sell

Current Market Cap: $60.95M

Find detailed analytics on PETS stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.